Development of Fulminant Type 1 Diabetes Mellitus in the Course of Treatment with Atezolizumab for Hepatocellular Carcinoma

  • Ikeda Munehiro
    Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan
  • Tamada Takashi
    Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan
  • Takebayashi Risa
    Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan
  • Okuno Gaku
    Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan
  • Yagura Iori
    Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan
  • Nakamori Shohei
    Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan
  • Matsumura Taishiro
    Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan
  • Yoshioka Takuto
    Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan
  • Kaneko Shizuka
    Department of Diabetes/Endocrinology/Metabolism, Takatsuki Red Cross Hospital, Japan
  • Kanda Naoki
    Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan

抄録

<p>A 71-year-old woman with recurring stage IV hepatocellular carcinoma (HCC) was admitted to our hospital while being treated with atezolizumab and bevacizumab and complained of fatigue, vomiting, and appetite loss. The following were noted on admission: serum glucose level, 633 mg/dL; metabolic acidemia (HCO3 of 19.5 mmol/L); remarkably low serum and urinary C-peptide levels (0.16 ng/mL and ≤1.5 μg/day, respectively); and urinary ketone body level, 4,197 μmol/L. She was diagnosed with atezolizumab-induced fulminant type 1 diabetes mellitus (T1DM), and insulin therapy improved the symptoms. To our knowledge, this a novel report of atezolizumab-induced fulminant T1DM in an HCC patient. </p>

収録刊行物

  • Internal Medicine

    Internal Medicine 62 (12), 1775-1779, 2023-06-15

    一般社団法人 日本内科学会

参考文献 (29)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ